Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

MBDA Score Independently Predictive of Relapsing RA

PLoS One; ePub 2018 May 23; Moghadam, et al

For patients with rheumatoid arthritis (RA) with stable low disease activity (LDA) who stopped TNF inhibitor (TNFi) treatment, a high baseline multi-biomarker disease activity (MBDA) score was independently predictive of disease relapse within 12 months. This according to a study that analyzed 439 RA patients post hoc who were randomized to stop TNFi treatment in the POET study. 3 indicators of disease relapse were assessed over 12 months: 1) restarting TNFi treatment, 2) escalation of any disease-modifying antirheumatic drug (DMARD) therapy and 3) physician-reported flare. MBDA score was assessed at baseline. Researchers found:

  • At baseline, 50.1%, 35.3%, and 14.6% of patients had low (<30), moderate (30−44), or high (>44) MBDA scores, respectively.
  • Within 12 months, 49.9% of patients had restarted TNFi medication, 59.0% had escalation of any DMARD, and 57.2% had ≥1 physician-reported flare.
  • MBDA score was associated with each indicator of relapse.
  • At least 1 indicator of relapse was observed in 59.5%, 68.4%, and 81.3% of patients with low, moderate or high MBDA scores, respectively.

Citation:

Moghadam MG, Lamers-Karnebeek FBG, Vonkeman HE, et al. Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment. [Published online ahead of print May 23, 2018]. PLoS One. doi:10.1371/journal.pone.0192425.

This Week's Must Reads

Burden of Sexual Dysfunction in Women with RA, J Rheumatol; ePub 2018 Sep 1; Puchner, et al

Medication Beliefs, Self-Efficacy Examined in RA, J Rheumatol; ePub 2018 Sep 15; McCulley, et al

Physical Activity Maintenance in Patients with RA, J Rheumatol; 2018 Aug; Nordgren, Fridén, et al

Effects of Flares in RA with Low Disease Activity, J Rheumatol; ePub 2018 Sep 1; Bechman, et al

RF and ACPAs Observed as Markers for Clinical RA, Clin Immunol; 2018 Oct; Lingampalli, et al

Must Reads in Rheumatoid Arthritis

Burden of Sexual Dysfunction in Women with RA, J Rheumatol; ePub 2018 Sep 1; Puchner, et al

Medication Beliefs, Self-Efficacy Examined in RA, J Rheumatol; ePub 2018 Sep 15; McCulley, et al

Physical Activity Maintenance in Patients with RA, J Rheumatol; 2018 Aug; Nordgren, Fridén, et al

Effects of Flares in RA with Low Disease Activity, J Rheumatol; ePub 2018 Sep 1; Bechman, et al

RF and ACPAs Observed as Markers for Clinical RA, Clin Immunol; 2018 Oct; Lingampalli, et al